company background image

Acorda Therapeutics NasdaqGS:ACOR Stock Report

Last Price


Market Cap







06 Oct, 2022


Company Financials
ACOR fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health1/6

ACOR Stock Overview

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States.

Acorda Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Acorda Therapeutics
Historical stock prices
Current Share PriceUS$0.37
52 Week HighUS$4.90
52 Week LowUS$0.26
1 Month Change-1.50%
3 Month Change-15.79%
1 Year Change-91.16%
3 Year Change-97.71%
5 Year Change-99.76%
Change since IPO-99.09%

Recent News & Updates

Aug 29

Acorda inks license deal with Asieris for pre-clinical drug

Commercial-stage biopharmaceutical company Acorda Therapeutics (NASDAQ:ACOR) announced a license agreement with Chinese biotech Asieris Pharmaceuticals on Monday for the preclinical candidate, Nepicastat. Per the terms, the two companies will collaborate to develop Nepicastat, a small molecule drug for non-psychiatric indications and therapeutic uses. In return, Acorda (ACOR) is set to receive $500K of upfront payment, up to $7M of fees based on regulatory milestones, and a royalty on future net sales. Acorda (ACOR) U.S. subsidiary, Biotie Therapies, Inc., owns the rights for Nepicastat. Read: In June, the nano-cap ACRO stock surged in reaction to the launch of its inhalational Parkinson’s disease drug Inbrija in Germany. However, the company shares remain ~90% below the year-ago level, as indicated in this graph.

Aug 19

Acorda Therapeutics announces resignation of COO

Acorda Therapeutics (NASDAQ:ACOR) has announced that Lauren Sabella, Chief Operating Officer, will resign from the Co. effective Sept. 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. Ms. Sabella’s responsibilities will be assumed by two of her current direct reports, Sofia Ali, Senior VP, Operations & Strategic Planning and Susan Way, Senior VP, Drug Development and Regulatory Affairs. ACOR +4.35% premarket to $0.48.

Shareholder Returns

ACORUS BiotechsUS Market

Return vs Industry: ACOR underperformed the US Biotechs industry which returned -19.3% over the past year.

Return vs Market: ACOR underperformed the US Market which returned -18.8% over the past year.

Price Volatility

Is ACOR's price volatile compared to industry and market?
ACOR volatility
ACOR Average Weekly Movement12.0%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: ACOR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ACOR's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

1995118Ron Cohen

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson’s disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas.

Acorda Therapeutics Fundamentals Summary

How do Acorda Therapeutics's earnings and revenue compare to its market cap?
ACOR fundamental statistics
Market CapUS$8.93m
Earnings (TTM)-US$118.84m
Revenue (TTM)US$122.01m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACOR income statement (TTM)
Cost of RevenueUS$41.77m
Gross ProfitUS$80.24m
Other ExpensesUS$199.09m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-4.88
Gross Margin65.77%
Net Profit Margin-97.41%
Debt/Equity Ratio210.4%

How did ACOR perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is ACOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACOR?

Other financial metrics that can be useful for relative valuation.

ACOR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.5x
Enterprise Value/EBITDA-7.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ACOR's PS Ratio compare to its peers?

ACOR PS Ratio vs Peers
The above table shows the PS ratio for ACOR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average22.9x
XCUR Exicure
NAVB Navidea Biopharmaceuticals
STAB Statera Biopharma
ENSC Ensysce Biosciences
ACOR Acorda Therapeutics

Price-To-Sales vs Peers: ACOR is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (22.9x).

Price to Earnings Ratio vs Industry

How does ACOR's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: ACOR is good value based on its Price-To-Sales Ratio (0.1x) compared to the US Biotechs industry average (14x)

Price to Sales Ratio vs Fair Ratio

What is ACOR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACOR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.07x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ACOR's Price-To-Sales Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of ACOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ACOR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ACOR's fair value for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Acorda Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Acorda Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Take a look at our analysis of ACOR’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.

Past Performance

How has Acorda Therapeutics performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ACOR is currently unprofitable.

Growing Profit Margin: ACOR is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: ACOR is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year.

Accelerating Growth: Unable to compare ACOR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACOR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).

Return on Equity

High ROE: ACOR has a negative Return on Equity (-135.19%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Acorda Therapeutics's financial position?

Financial Health Score


Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ACOR's short term assets ($76.5M) exceed its short term liabilities ($41.1M).

Long Term Liabilities: ACOR's short term assets ($76.5M) do not cover its long term liabilities ($277.3M).

Debt to Equity History and Analysis

Debt Level: ACOR's net debt to equity ratio (184.1%) is considered high.

Reducing Debt: ACOR's debt to equity ratio has increased from 47.7% to 210.4% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACOR has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ACOR has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31.8% each year

Discover healthy companies


What is Acorda Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Acorda Therapeutics Dividend Yield vs Market
How does Acorda Therapeutics dividend yield compare to the market?
SegmentDividend Yield
Company (Acorda Therapeutics)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.8%
Analyst forecast in 3 Years (Acorda Therapeutics)n/a

Notable Dividend: Unable to evaluate ACOR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACOR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACOR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACOR's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ACOR has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Ron Cohen (66 yo)





Dr. Ron Cohen, M.D., has been the Founder of Acorda Therapeutics, Inc. since 1995 and has been its Chief Executive Officer and President since 1995. Dr. Cohen served as Principal in the startup of Advanced...

CEO Compensation Analysis

Ron Cohen's Compensation vs Acorda Therapeutics Earnings
How has Ron Cohen's remuneration changed compared to Acorda Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a


Mar 31 2022n/an/a


Dec 31 2021US$2mUS$743k


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021n/an/a


Dec 31 2020US$2mUS$796k


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020n/an/a


Dec 31 2019US$2mUS$796k


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019n/an/a


Dec 31 2018US$2mUS$796k


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018n/an/a


Dec 31 2017US$2mUS$792k


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017n/an/a


Dec 31 2016US$3mUS$773k


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016n/an/a


Dec 31 2015US$3mUS$769k


Compensation vs Market: Ron's total compensation ($USD1.65M) is above average for companies of similar size in the US market ($USD772.75K).

Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: ACOR's management team is considered experienced (4.2 years average tenure).

Board Members

Experienced Board: ACOR's board of directors are seasoned and experienced ( 20.8 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

NasdaqGS:ACOR Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
17 Mar 22SellUS$3,895Ron CohenIndividual2,289US$1.70

Ownership Breakdown

What is the ownership structure of ACOR?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders152,3280.6%
Hedge Funds2,395,6689.8%
General Public17,508,12472.0%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 118.8%.

Top Shareholders

Top 25 shareholders own 27.71% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
Davidson Kempner Capital Management LP
Canyon Capital Advisors LLC
Renaissance Technologies LLC
901,318$330.7k27.45%no data
Acadian Asset Management LLC
682,670$250.5k45.95%no data
Millennium Management LLC
311,509$114.3k661.24%no data
The Vanguard Group, Inc.
158,061$58.0k-53.72%no data
Virtu Financial LLC, Asset Management Arm
145,318$53.3k0%no data
BlackRock, Inc.
139,522$51.2k-15.68%no data
Ron Cohen
118,001$43.3k-8.95%no data
HN Saltoro Capital, LP
Bridgeway Capital Management, LLC
101,706$37.3k-58.33%no data
Wells Fargo & Company, Securities and Brokerage Investments
74,582$27.4k49.75%no data
PGIM, Inc.
60,200$22.1k0%no data
Geode Capital Management, LLC
46,721$17.1k0%no data
Susquehanna International Group, LLP, Asset Management Arm
45,880$16.8k0%no data
Hudson River Trading LLC, Asset Management Arm
39,319$14.4k0%no data
State Street Global Advisors, Inc.
31,648$11.6k0%no data
UBS Asset Management
28,698$10.5k919.47%no data
Two Sigma Securities, LLC, Asset Management Arm
27,692$10.2k0%no data
Tower Research Capital LLC
27,234$10.0k4603.63%no data
United Asset Strategies Inc.
27,100$9.9k0%no data
Northern Trust Global Investments
26,118$9.6k-1.92%no data
Susquehanna Fundamental Investments, LLC
22,600$8.3k0%no data
Two Sigma Advisers, LP
14,400$5.3k0%no data
Massey Quick Simon & Co., LLC
14,211$5.2k0%no data

Company Information

Acorda Therapeutics, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Acorda Therapeutics, Inc.
  • Ticker: ACOR
  • Exchange: NasdaqGS
  • Founded: 1995
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$8.928m
  • Shares outstanding: 24.33m
  • Website:

Number of Employees


  • Acorda Therapeutics, Inc.
  • 420 Saw Mill River Road
  • Ardsley
  • New York
  • 10502
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CDG0DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2006
ACORNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2006

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/06 00:00
End of Day Share Price2022/10/06 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.